Differences in study duration and patient populations complicate direct comparison, but the mechanistic rationale and sheer magnitude of effect strongly favor Retatrutide for monotherapy applications
This article is exclusive to STAT+ subscribers Unlock this article plus daily coverage and analysis of the biotech sector by subscribing to STAT+

The current evidence base primarily from animal studies and limited human trials suggests the following potential applications: Improved sleep quality increased proportion of slow-wave sleep, reduced sleep latency, fewer nocturnal cortisol spikes Cortisol normalisation reduced HPA hyperactivation, particularly relevant in high-stress or metabolically burdened patients Nociceptive effects several studies indicate DSIP modulates pain processing, with implications for patients whose poor sleep is pain-driven (3) Antioxidant activity may reduce oxidative stress markers, which are elevated in both sleep-deprived and insulin-resistant individuals Neuroendocrine support preliminary evidence of effects on LH, FSH, and somatostatin hormones that regulate testosterone, oestrogen, and growth hormone release Potential stress adaptation some data suggest DSIP may reduce the physiological stress response magnitude without blunting alertness It is important to be precise here

Starting the peptide early in a Retatrutide protocol, before substantial weight loss occurs, may provide better skin outcomes than waiting until loose skin develops
Our experts weigh in on whether this supplement is worth the hype or if it poses unnecessary risks
Our care team reviews your compounding pharmacys BUD policy to ensure youre aligned